Nexus Pharmaceuticals has chosen Pleasant Prairie as the location of its first sterile injectable drug production facility. The new $85 million operation will support the company’s specialty and generic drug production, much of which is currently contracted out to third-party manufacturers in Europe.
Nexus, a woman-owned, privately held company based in Lincolnshire, Illinois, produces injectable drugs for therapeutic use in anesthesia, oncology, neurology and cardiovascular applications. The Pleasant Prairie project is expected to create 77 jobs in high-tech production, analytical testing, engineering, quality control and supply chain management.
“We are looking forward to executing the next phase of our growth plan in Wisconsin,” said Nexus CEO Mariam Darsot. “The addition of our Wisconsin facility will enable Nexus to produce a more stable and reliable supply of sterile injectables, a category that is particularly susceptible to drug shortages.”
Nexus plans a multi-phase project with a total investment of $250 million over 10 years. Construction on the 100,000-square-foot production facility, the project’s first phase, begins next month. The company expects construction to be complete in 2021 and production to start in 2022 after all regulatory approvals are secured.
WEDC is supporting the project with up to $1.5 million in state income tax credits over the next four years. The actual amount of tax credits Nexus will receive is contingent upon the number of jobs created and the amount of capital investment during that period.
